FOXP3 and adenocarcinoma: Treatment with anti-CD25 antibody decreased splenic Foxp3+CD25+ cells by 95% (Fig. 3c, left panel), decreased lung-associated Foxp3+ cells by 65% (Fig. 3c, right panel) and decreased the multiplicity of IO33 adenocarcinomas by 80% (Fig. 3d).